3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Carcinoma, Non-Small-Cell Lung
9
Lung Neoplasms
7
Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
2
Advanced Solid Tumors
2
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non Small Lung Cancer
1
Mesothelioma
1
KRAS p.G12C Mutant Advanced Solid Tumors
1
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Brain Neoplasms
1
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
1
Advanced Solid Tumor
1
Interventions
Bevacizumab
56
Cetuximab
50
Fluorouracil
45
Leucovorin
39
Oxaliplatin
38
pembrolizumab
31
Specimen Handling
27
Irinotecan
25
Magnetic Resonance Spectroscopy
17
Biopsy
17
Nivolumab
15
HMPL-013
13
Folfox protocol
13
Capecitabine
13
Gemcitabine
12
Cisplatin
12
trifluridine tipiracil drug combination
11
Panitumumab
11
Carboplatin
11
Pemetrexed
9
IFL protocol
9
encorafenib
8
balstilimab
8
Standard of Care
8
Paclitaxel
8
Early Intervention, Educational
8
130-nm albumin-bound paclitaxel
8
fludarabine
7
atezolizumab
7
Educational Status
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
sotorasib
×
90 days
×
Clear all
NCT05198934
2026-04-27
CodeBreak300
Amgen
Phase 3
Completed
160 enrolled
1 FDA
NCT06252649
2026-04-24
CodeBreaK 301
Amgen
Phase 3
Recruiting
450 enrolled